RGBP Regen BioPharma Discovers Potential New Way to Improve Outcomes from Cancer Surgery Using Combination of Cannabidiol and NR2F6 Inhibition
' The new data demonstrates enhanced ability to reduce cancer growth in an efficacious manner while appearing not to induce any form of toxicity.
NR2F6 using patent-pending compounds developed by the Company results in selective inhibition of new blood vessels under conditions associated with cancer and wet macular degeneration. The data, which was obtained using human umbilical vein endothelial cells (HUVEC)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.